跳转至内容
Merck
CN

主要文件

查看所有文档

O-023

Oxazepam glucuronide solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C21H19ClN2O8
化学文摘社编号:
6801-81-6
分子量:
462.84
UNSPSC Code:
41116107
PubChem Substance ID:
329818831
EC Number:
200-659-6
MDL number:
MFCD00872000
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentration

100 μg/mL in methanol

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

O[C@@H]1[C@@H](O)[C@H](OC2N=C(c3ccccc3)c4cc(Cl)ccc4NC2=O)O[C@@H]([C@H]1O)C(O)=O

InChI

1S/C21H19ClN2O8/c22-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)24-19(18(28)23-12)32-21-16(27)14(25)15(26)17(31-21)20(29)30/h1-8,14-17,19,21,25-27H,(H,23,28)(H,29,30)/t14-,15-,16+,17-,19?,21-/m0/s1

InChI key

FIKQKGFUBZQEBL-IFBJMGMISA-N

General description

Oxazepam glucuronide is a major urinary metabolite of the benzodiazepine drug, oxazepam. Oxazepam, marketed as Alepam, Medopam, or Murelax®, has been used extensively since the 1960s for treatment of anxiety and insomnia and in the control of symptoms of alcohol withdrawal. This certified reference solution is suitable for GC/MS or LC/MS applications with oxazepam or oxazepam glucuronide such as urine drug testing, pain prescription monitoring, toxicology analysis, or forensic testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Murelax is a registered trademark of Aspen Pharma Pty Ltd
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

存储类别

3 - Flammable liquids

wgk

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

监管及禁止进口产品

此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

实验方案

使用UHPLC/MS（TOF）检测不同酶水解条件处理的尿液中药物和代谢物

为了使用β-葡糖醛酸酶优化水解，必须对每种待分析的葡糖苷酸代谢物进行某些因素的评估，例如孵育时间、温度、水解pH、酶源和酶浓度。

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

J Sonne et al.
European journal of clinical pharmacology, 35(4), 385-389 (1988-01-01)
Six healthy volunteers received oxazepam 15 mg i.v. and orally at an interval of at least one week. The kinetic variables of i.v. oxazepam were: elimination half-life (t1/2 beta) 6.7 h, total clearance (CL) 1.07 ml.min-1.kg-1, volume of distribution (Vc)
Beitske E Smink et al.
British journal of clinical pharmacology, 66(4), 556-560 (2008-07-30)
To measure and compare the concentration-time profiles of oxazepam and oxazepam glucuronide in blood, serum and oral fluid within the scope of roadside testing. Biological samples were collected from eight male subjects after ingestion of 15 or 30 mg oxazepam
A M van Hecken et al.
British journal of clinical pharmacology, 20(3), 225-234 (1985-09-01)
Single dose pharmacokinetics of oxazepam, 30 mg, have been studied in six healthy male volunteers in the absence of diflunisal and during continuous treatment with diflunisal 500 mg twice daily. During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased
查看所有相关文献

全球贸易项目编号

货号GTIN
O-023-1ML04061834211792